Compare Novartis AG (NVS) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Charles Schwab Corporation Common Stock — how do they compare? Novartis AG trades at $142.86 (market cap $268.57B), while Charles Schwab Corporation Common Stock trades at $97 (market cap $167.52B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Charles Schwab Corporation Common Stock for 85 Days on average.
| NVS | SCHW | |
|---|---|---|
Market Cap | $268.57B | $167.52B |
Volume | 1,532,573 | 6,554,126 |
Sector | Health | Financials |
52-Week High | $168.62 | $113.65 |
52-Week Low | $121.80 | $85.35 |
Typical Hold Time | 82 Days | 85 Days |
Enterprise Value | $309.89B | $153.97B |
Dividend Yield | 3.31% | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Charles Schwab (SCHW) trades at $95.58, down 1.26% today, with a bearish technical signal. The stock shows strong fundamentals, with Q2 2026 EPS beating expectations at $1.62 and revenue growth to $23.92B in 2025. Analyst consensus is bullish, with a $119.92 price target, supported by recent news of a secondary listing on the Texas Stock Exchange and AI integration for advisors.
Outlook remains positive due to earnings momentum and market share gains, but risks include competitive pressures and interest rate sensitivity. The stock offers upside from current levels if execution continues, though technical weakness may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
